Triple combination therapy of favipiravir plus two monoclonal antibodies eradicates influenza virus from nude mice
暂无分享,去创建一个
[1] M. Kiso,et al. Baloxavir marboxil treatment of nude mice infected with influenza A virus. , 2019, The Journal of infectious diseases.
[2] T. Kuwahara,et al. Human-to-Human Transmission of Influenza A(H3N2) Virus with Reduced Susceptibility to Baloxavir, Japan, February 2019 , 2019, Emerging infectious diseases.
[3] F. Hayden,et al. Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza. , 2019, The Journal of infectious diseases.
[4] W. Schaffner,et al. Outcomes of immunocompromised adults hospitalized with laboratory-confirmed influenza in the United States, 2011-2015. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] F. Hayden,et al. Influenza virus polymerase inhibitors in clinical development , 2019, Current opinion in infectious diseases.
[6] T. Kuwahara,et al. Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018 , 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[7] H. Ikematsu,et al. Consecutive influenza surveillance of neuraminidase mutations and neuraminidase inhibitor resistance in Japan , 2019, Influenza and other respiratory viruses.
[8] M. Kiso,et al. Isolation and Characterization of Human Monoclonal Antibodies That Recognize the Influenza A(H1N1)pdm09 Virus Hemagglutinin Receptor-Binding Site and Rarely Yield Escape Mutant Viruses , 2018, Front. Microbiol..
[9] Y. Kawaoka,et al. Differences in the ease with which mutant viruses escape from human monoclonal antibodies against the HA stem of influenza A virus. , 2018, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[10] D. Goldhill,et al. The mechanism of resistance to favipiravir in influenza , 2018, Proceedings of the National Academy of Sciences.
[11] I. Wilson,et al. Recurring and Adaptable Binding Motifs in Broadly Neutralizing Antibodies to Influenza Virus Are Encoded on the D3-9 Segment of the Ig Gene , 2018, Cell Host & Microbe.
[12] F. Hayden,et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents , 2018, The New England journal of medicine.
[13] J. McCaw,et al. Characterization of Influenza B Virus Variants with Reduced Neuraminidase Inhibitor Susceptibility , 2018, Antimicrobial Agents and Chemotherapy.
[14] M. Kiso,et al. Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus , 2018, The Journal of infectious diseases.
[15] J. Tavel,et al. Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial , 2018, Clinical Pharmacokinetics.
[16] Honglin Chen,et al. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses , 2017, Science Translational Medicine.
[17] F. Dubovsky,et al. A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers. , 2017, Biologicals : journal of the International Association of Biological Standardization.
[18] Rob Lambkin-Williams,et al. Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model , 2017, Antimicrobial Agents and Chemotherapy.
[19] M. Kiso,et al. A Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus Particle Release , 2017, EBioMedicine.
[20] Z. Memish,et al. Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options , 2014, Lancet. Infectious Diseases (Print).
[21] Y. Iba,et al. Receptor mimicry by antibody F045–092 facilitates universal binding to the H3 subtype of influenza virus , 2014, Nature Communications.
[22] John Steel,et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop , 2012, Nature.
[23] N. S. Laursen,et al. Highly Conserved Protective Epitopes on Influenza B Viruses , 2012, Science.
[24] Ha T. Nguyen,et al. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. , 2012, Antiviral therapy.
[25] J. Skehel,et al. A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins , 2011, Science.
[26] M. Boeckh,et al. H275Y Mutant Pandemic (H1N1) 2009 Virus in Immunocompromised Patients , 2011, Emerging infectious diseases.
[27] R. Webster,et al. Adaptation of Pandemic H1N1 Influenza Viruses in Mice , 2010, Journal of Virology.
[28] M. Jonges,et al. Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. , 2009, The Journal of infectious diseases.
[29] F. Ennis,et al. Recovery from a viral respiratory infection. I. Influenza pneumonia in normal and T-deficient mice. , 1981, Journal of immunology.